Guggenheim Capital LLC grew its holdings in Edwards Lifesciences Corp (NYSE:EW) by 15.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 652,541 shares of the medical research company’s stock after purchasing an additional 88,931 shares during the quarter. Guggenheim Capital LLC owned 0.31% of Edwards Lifesciences worth $73,549,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also bought and sold shares of the company. Jefferies Group LLC lifted its stake in Edwards Lifesciences by 29.6% in the fourth quarter. Jefferies Group LLC now owns 77,687 shares of the medical research company’s stock worth $8,756,000 after acquiring an additional 17,756 shares during the last quarter. Compton Capital Management Inc. RI lifted its stake in Edwards Lifesciences by 84.4% in the fourth quarter. Compton Capital Management Inc. RI now owns 4,655 shares of the medical research company’s stock worth $525,000 after acquiring an additional 2,130 shares during the last quarter. JOYN Advisors Inc. purchased a new position in Edwards Lifesciences in the fourth quarter worth approximately $980,000. Gardner Lewis Asset Management L P purchased a new position in Edwards Lifesciences in the fourth quarter worth approximately $1,730,000. Finally, Fred Alger Management Inc. lifted its stake in Edwards Lifesciences by 610.3% in the fourth quarter. Fred Alger Management Inc. now owns 152,528 shares of the medical research company’s stock worth $17,191,000 after acquiring an additional 131,053 shares during the last quarter. 82.86% of the stock is owned by institutional investors and hedge funds.
EW has been the subject of a number of recent research reports. Canaccord Genuity reiterated a “buy” rating and issued a $137.00 price target on shares of Edwards Lifesciences in a research note on Wednesday, November 29th. BMO Capital Markets reiterated a “buy” rating and issued a $137.00 price target on shares of Edwards Lifesciences in a research note on Friday, December 8th. Cowen set a $135.00 price target on shares of Edwards Lifesciences and gave the stock a “buy” rating in a research note on Sunday, December 10th. JPMorgan Chase & Co. downgraded shares of Edwards Lifesciences from an “overweight” rating to a “neutral” rating in a research note on Tuesday, January 2nd. Finally, Evercore ISI initiated coverage on shares of Edwards Lifesciences in a research note on Wednesday, January 3rd. They issued an “outperform” rating and a $140.00 price target for the company. Three analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $141.15.
Shares of Edwards Lifesciences Corp (NYSE:EW) opened at $139.32 on Monday. The firm has a market cap of $29,260.50, a P/E ratio of 48.38, a PEG ratio of 2.06 and a beta of 0.56. The company has a current ratio of 1.80, a quick ratio of 1.41 and a debt-to-equity ratio of 0.15. Edwards Lifesciences Corp has a 12-month low of $91.30 and a 12-month high of $140.07.
Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, February 1st. The medical research company reported $0.94 earnings per share for the quarter, topping the consensus estimate of $0.91 by $0.03. The business had revenue of $888.50 million during the quarter, compared to the consensus estimate of $868.45 million. Edwards Lifesciences had a net margin of 18.11% and a return on equity of 27.78%. The company’s revenue was up 15.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.75 EPS. research analysts expect that Edwards Lifesciences Corp will post 4.49 earnings per share for the current fiscal year.
Edwards Lifesciences declared that its Board of Directors has approved a share repurchase plan on Thursday, December 7th that allows the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization allows the medical research company to purchase shares of its stock through open market purchases. Shares repurchase plans are often a sign that the company’s board of directors believes its stock is undervalued.
TRADEMARK VIOLATION WARNING: This piece was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.americanbankingnews.com/2018/03/12/guggenheim-capital-llc-acquires-88931-shares-of-edwards-lifesciences-corp-ew.html.
About Edwards Lifesciences
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.